Neurotech International Ltd has released a press release.
Positive Human PK Study Results for NTI164
Filed with ASX ·
6ix hasn’t read this filing yet.
Neurotech International Ltd. on 6ix
Story so far
Earlier from Neurotech International
- NTI164 Preclinical Toxicology Studies Update
- Appendix 4D and Half Year Accounts
- Positive Opinion on OMPD for NTI164 in Europe
- NTI Signs Development Agreement for Cannabinoid Therapies
- Neurotech Receives $2.44 Million R&D Tax Incentive Refund
Later from Neurotech International
- Appendix 4E & Annual Report to shareholders
- US FDA Rare Pediatric Disease Designation in Rett syndrome
- Neurotech receives $4.73m R&D Tax Incentive Refund
- Trading Halt
- Binding Commitments Received for a $4 Million Placement
Follow Neurotech International into a list and get an email when it puts out news.
Follow Neurotech International